S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

Minerva Neurosciences Stock Forecast, Price & News

+0.28 (+8.46%)
(As of 07/1/2022 03:55 PM ET)
Today's Range
50-Day Range
52-Week Range
400 shs
Average Volume
20,100 shs
Market Capitalization
$19.17 million
P/E Ratio
Dividend Yield
Price Target

Minerva Neurosciences MarketRank™ Forecast

Analyst Rating
3.00 Rating Score
1,014.2% Upside
$40.00 Price Target
Short Interest
1.01% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.72mentions of Minerva Neurosciences in the last 14 days
Based on 4 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($8.56) to ($5.80) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.25 out of 5 stars

Medical Sector

228th out of 1,428 stocks

Pharmaceutical Preparations Industry

112th out of 680 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive NERV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Minerva Neurosciences and its competitors with MarketBeat's FREE daily newsletter.

Minerva Neurosciences logo

About Minerva Neurosciences (NASDAQ:NERV) Stock

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

NERV Stock News Headlines

Minerva Neurosciences, Inc. (NERV)
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
1 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$41.18 million
Book Value
$1.49 per share


Free Float
Market Cap
$19.17 million

Minerva Neurosciences Frequently Asked Questions

Should I buy or sell Minerva Neurosciences stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Minerva Neurosciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Minerva Neurosciences stock.
View analyst ratings for Minerva Neurosciences
or view top-rated stocks.

What is Minerva Neurosciences' stock price forecast for 2022?

1 analysts have issued 12-month target prices for Minerva Neurosciences' stock. Their NERV stock forecasts range from $40.00 to $40.00. On average, they anticipate Minerva Neurosciences' share price to reach $40.00 in the next twelve months. This suggests a possible upside of 1,014.2% from the stock's current price.
View analysts' price targets for Minerva Neurosciences
or view top-rated stocks among Wall Street analysts.

How has Minerva Neurosciences' stock performed in 2022?

Minerva Neurosciences' stock was trading at $6.4080 on January 1st, 2022. Since then, NERV stock has decreased by 44.0% and is now trading at $3.59.
View the best growth stocks for 2022 here

When is Minerva Neurosciences' next earnings date?

Minerva Neurosciences is scheduled to release its next quarterly earnings announcement on Monday, August 1st 2022.
View our earnings forecast for Minerva Neurosciences

How were Minerva Neurosciences' earnings last quarter?

Minerva Neurosciences, Inc. (NASDAQ:NERV) posted its quarterly earnings data on Wednesday, May, 4th. The biopharmaceutical company reported ($1.84) earnings per share for the quarter, missing the consensus estimate of ($1.60) by $0.24.
View Minerva Neurosciences' earnings history

When did Minerva Neurosciences' stock split? How did Minerva Neurosciences' stock split work?

Minerva Neurosciences's stock reverse split on Tuesday, June 21st 2022. The 1-8 reverse split was announced on Tuesday, June 21st 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, June 21st 2022. An investor that had 100 shares of Minerva Neurosciences stock prior to the reverse split would have 13 shares after the split.

Who are Minerva Neurosciences' key executives?

Minerva Neurosciences' management team includes the following people:
  • Dr. Remy Luthringer Ph.D., Exec. Chairman & CEO (Age 61, Pay $1.19M)
  • Mr. Geoffrey Robin Race F.C.M.A., FCMA, M.B.A., MBA, Pres (Age 61, Pay $880.44k)
  • Mr. Frederick W. Ahlholm CPA, CPA, Sr. VP, CFO & Sec. (Age 56, Pay $610.68k)
  • Dr. Michael Davidson M.D., Chief Medical Officer (Age 72, Pay $657.47k)
  • Mr. Joseph Reilly, Sr. VP & COO (Age 47)
  • Mr. William B. Boni, VP of Investor Relations & Corp. Communications (Age 70)
  • Dr. Jay B. Saoud Ph.D., Consultant (Age 63)
  • Dr. Ramana Kuchibhatla Ph.D., Sr. VP and Head of R&D

What other stocks do shareholders of Minerva Neurosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Minerva Neurosciences investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), PTC Therapeutics (PTCT), Immunomedics (IMMU), VBI Vaccines (VBIV), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Moderna (MRNA), T2 Biosystems (TTOO) and Advanced Micro Devices (AMD).

What is Minerva Neurosciences' stock symbol?

Minerva Neurosciences trades on the NASDAQ under the ticker symbol "NERV."

How do I buy shares of Minerva Neurosciences?

Shares of NERV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Minerva Neurosciences' stock price today?

One share of NERV stock can currently be purchased for approximately $3.59.

How much money does Minerva Neurosciences make?

Minerva Neurosciences (NASDAQ:NERV) has a market capitalization of $19.17 million and generates $41.18 million in revenue each year. The biopharmaceutical company earns $-49,910,000.00 in net income (profit) each year or ($9.60) on an earnings per share basis.

How many employees does Minerva Neurosciences have?

Minerva Neurosciences employs 9 workers across the globe.

How can I contact Minerva Neurosciences?

Minerva Neurosciences' mailing address is 1601 TRAPELO ROAD SUITE 286, WALTHAM MA, 02451. The official website for Minerva Neurosciences is www.minervaneurosciences.com. The biopharmaceutical company can be reached via phone at (617) 600-7373 or via email at wboni@minervaneurosciences.com.

This page (NASDAQ:NERV) was last updated on 7/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.